PROM1 and colorectal carcinoma: Novel biomarkers such as O6-methylguanine-DNA methyltransferase (MGMT) and CD133 have been proposed as useful tools for the diagnosis, prognosis, and follow-up of CRC and for the detection of relapse[7].